LUNG CANCER

Phase 3 data show oral sunvozertinib beats platinum chemo in EGFR exon 20ins NSCLC, boosting PFS and responses with tolerable safety.

ELCC 2026 spotlights lung cancer breakthroughs—ADCs, EGFR combo sequencing, HER2 TKIs and SCLC bispecifics—reshaping treatment choices.

Aglatimagene besadenovec intratumoral gene therapy plus valacyclovir shows durable survival in ICI-resistant advanced NSCLC, fueling pivotal phase 3 plans.

Phase 3 NSCLC study of eftilagimod alfa with pembrolizumab and chemo stops early after futility review, raising questions about LAG-3 strategy.

IASLC TTLC 2026 spotlights patient voices, ctDNA MRD, EGFR co-mutations, and ADCs—plus real-world gaps in testing and multidisciplinary lung care.

An interview with Joshua Reuss, MD, thoracic medical oncologist at Georgetown University and co-author of the guidelines.

FDA clears zongertinib for HER2-mutant advanced nonsquamous NSCLC, showing strong responses and promising brain metastasis activity.

Explore frontline chemo‑immunotherapy choices in extensive-stage SCLC, NCCN updates, and why patient drop-off shapes second- and third-line care.

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid biopsies shaping 2026 treatment.

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and infusion reactions while maintaining efficacy.

Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion–positive NSCLC, signaling a potential new standard and expanding genomic testing.

FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable safety.

A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need for improved access to targeted therapies.

The FDA reviews ivonescimab for advanced lung cancer treatment, showing promising trial results and potential to enhance patient outcomes post-TKI therapy.

A new study reveals that savolitinib and osimertinib significantly enhance survival in advanced EGFR-mutated lung cancer, outperforming traditional chemotherapy.

New research highlights the potential of nogapendekin alfa inbakicept to enhance survival in patients with advanced lung cancer resistant to standard therapies.

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous non–small cell lung cancer.

A groundbreaking biologics license application for ivonescimab targets advanced lung cancer, promising improved outcomes for patients with EGFR mutations.

The FDA designates zoldonrasib as a breakthrough therapy for KRAS G12D-mutated lung cancer, highlighting its promising efficacy and safety profile.

A new trial explores the effectiveness of calderasib combined with pembrolizumab for advanced lung cancer patients with the KRAS G12C mutation.

Sevabertinib receives breakthrough therapy designation for treating advanced HER2-mutant non-small cell lung cancer, promising new hope for patients.

2025 marks a transformative year in thoracic oncology, showcasing groundbreaking FDA approvals for targeted therapies in lung cancer treatment.

A new study reveals that common chronic medications do not impact the effectiveness of immune checkpoint inhibitors in metastatic lung cancer treatment.